September 30, 2015

Mitsubishi Tanabe Pharma Corporation
Revision to Consolidated Financial Forecastsfor Fiscal Year Ending March 31, 2016

Osaka, Japan, September 30, 2015 --- Mitsubishi Tanabe Pharma Corporation (Head office:Chuo-ku, Osaka, President and Representative Director: Masayuki Mitsuka) announced today arevision to the 2Q and full-year consolidated financial forecasts for the fiscal year ending March 31,
2016, which were announced on May 8, 2015.

1.

Revised 2Q consolidated financial forecasts for the fiscal year ending March 31, 2016 (April 1,2015 to September 30, 2015)

Previous forecast (A)Revised forecast (B)Difference (B-A)
Percentage change (%)

Sales

Operatingincome

Ordinary
incomeNet income
attributable toshareholders ofthe CompanyNet income
per share

Millions of yen

Millions of yen

Millions of yen

Millions of yen

Yen

191,500

28,00028,00019,00033.87

200,000

38,50038,00025,500

45.46

8,500

10,50010,000

6,500

－

4.4

37.5

35.7

34.2

－

198,883

34,95435,45532,51857.97(Reference) Results in thesame period of the previous
fiscal year

2.

Revised consolidated financial forecasts for the fiscal year ending March 31, 2016 (April 1, 2015
to March 31, 2016)

Sales

OperatingincomeOrdinaryincome

Net income
attributable toshareholders ofthe Company

Net income
per share

Millions of yen

Millions of yen

Millions of yen

Millions of yen

Yen

396,000

67,50067,00040,50072.19

Revised forecast (B)418,000

82,00081,00046,00082.00

Difference (B-A)

22,00014,50014,000

5,500

－

5.6

21.5

20.9

13.6

－

415,124

67,13367,65439,502

70.41

Previous forecast (A)Percentage change (%)(Reference) Results in thesame period of the previous
fiscal year

3.

Reason for revision:
In the first half of the fiscal year, net sales are expected to surpass the level of the previously

announced forecast due to favorable sales of vaccines and others in domestic ethical drug operations
and to favorable growth in royalty revenues from Invokana and other products.
In profits, operating income, ordinary income, and net income attributable to shareholders of theCompany for the first half of the fiscal year are all expected to exceed the previously announced
forecasts. This is a result of the growth in sales and of a decline in R&D and other SG&A expenses
because certain expenses will be incurred in the second half.
In regard to the full-year forecast, in the second half of the fiscal year we expect to receive
lump-sum payments accompanying the conclusion of a licensing agreement with Biogen related toMT-1303, a treatment agent for autoimmune diseases, and accompanying a patent and know-how
transfer agreement and future agreements with Amgen and Dezima regarding TA-8995, a treatment
agent for dyslipidemia. For the full fiscal year, net sales are expected to substantially exceed thepreviously announced forecast.
In addition, licensing expenses which were not occurred in the first half and R&D expenses will be
incurred in the second half. As a result, we expect SG&A expenses to increase in the second half ofthe fiscal year. Nonetheless, operating income and ordinary income for the full-year are expected toexceed the previously announced forecast.
Accompanying the acceleration of the structural reforms that are currently being implemented, weexpect to incur additional extraordinary losses in the second half. However, full-year net income
attributable to shareholders of the Company is expected to exceed the previously announced
forecast.
Note: The above results forecasts reflect judgments and assumptions that are based on information
available at the present point in time. For any of a number of reasons, actual results might differ
materially from these forecasts.

End